aldosterone and Chronic Kidney Diseases studies

Research Excerpts

Excerpt	Relevance	Reference
"These observations support a putative benefit of spironolactone treatment in CKD-associated vascular calcification."	9.41	Protective effects of spironolactone on vascular calcification in chronic kidney disease. ( Alesutan, I; Auer, T; Buehling, SS; Degenhart, G; Feger, M; Grebe, S; Hammer, F; Hauser, T; Krane, V; Lang, F; Malzahn, U; Masyout, J; Pasch, A; Tuffaha, R; Voelkl, J; Wanner, C, 2021)
"The purpose of this study was to evaluate the effects of spironolactone on dialysis patients with refractory hypertension and possible adverse effects."	9.19	Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. ( Chen, J; Ni, X; Wu, F; Xia, M; Ying, G; Zhang, J; Zhang, P, 2014)
" We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease."	9.17	L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013)
"As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia."	7.74	Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008)
"Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk."	6.50	Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014)
"Hyperkalemia is a common complication of RAASi therapy and is associated with an increased risk of multiple adverse outcomes."	5.91	Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. ( Johnson, M; McMahon, G; Morrison, FJ; Su, M; Turchin, A, 2023)
"Hyperkalemia is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD)."	5.72	Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective. ( Fischer, B; Serra, A; Telser, H, 2022)
"Residual hypertension was defined as persistent hypertension > 140/90 mmHg or requiring anti-hypertensive medications 1 year after surgery."	5.62	Comparison of cystatin C-based and creatinine-based glomerular filtration rate in the prediction of postoperative residual hypertension in aldosterone-producing adenoma patients after adrenalectomy. ( Chang, CC; Chen, CW; Chiu, YW; Hung, CS; Liao, SC; Lin, YH; Liu, KL; Tsai, CH; Tsai, IJ; Wu, VC, 2021)
"Aldosterone has an important role in the progression of renal fibrosis."	5.51	Aldosterone induces renal fibrosis by promoting HDAC1 expression, deacetylating H3K9 and inhibiting klotho transcription. ( Cheng, P; Gu, Y; Lai, L; Xue, J; Yan, M, 2019)
" Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients."	5.46	Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017)
"These observations support a putative benefit of spironolactone treatment in CKD-associated vascular calcification."	5.41	Protective effects of spironolactone on vascular calcification in chronic kidney disease. ( Alesutan, I; Auer, T; Buehling, SS; Degenhart, G; Feger, M; Grebe, S; Hammer, F; Hauser, T; Krane, V; Lang, F; Malzahn, U; Masyout, J; Pasch, A; Tuffaha, R; Voelkl, J; Wanner, C, 2021)
"The purpose of this study was to evaluate the effects of spironolactone on dialysis patients with refractory hypertension and possible adverse effects."	5.19	Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. ( Chen, J; Ni, X; Wu, F; Xia, M; Ying, G; Zhang, J; Zhang, P, 2014)
" We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease."	5.17	L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013)
"We aimed to assess the effect of aliskiren treatment on blood pressure, albuminuria, and kidney function in patients with chronic kidney disease (CKD)."	5.17	Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. ( Abe, M; Baba, S; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Takashima, H, 2013)
"Aliskiren combined with olmesartan reduces proteinuria in CKD patients."	5.16	Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. ( Itabashi, M; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Sugiura, H; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K, 2012)
"Studies in animals and humans show that increased tissue acidity raises the renal levels of endothelin, angiotensin II, aldosterone, and ammoniagenesis, thereby worsening renal fibrosis and causing progression of CKD."	4.98	Retarding progression of chronic kidney disease: use of modalities that counter acid retention. ( Kraut, JA; Madias, NE, 2018)
" The medical records of diabetic cats were searched for the keywords 'hypertension', 'blood pressure', 'amlodipine', 'benazepril' and 'telmisartan' to identify cats with SH, which was defined as systemic arterial blood pressure (SABP) ⩾160 mmHg, documented at least twice, over several days."	4.31	Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension. ( Hess, RS; Williams, JG, 2023)
"Longstanding primary aldosteronism (PA) has deleterious effects on renal function, often masked until treatment (adrenalectomy or spironolactone) is initiated."	3.85	Effects of Treating Primary Aldosteronism on Renal Function. ( Deinum, J; Kramers, BJ; Kramers, C; Lenders, JW, 2017)
"As oxonic acid diet increased plasma renin activity, plasma aldosterone, and urine K to Na ratio, these changes may play a significant role in the harmful cardiovascular actions of hyperuricemia."	3.74	Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. ( Eräranta, A; Kööbi, P; Kurra, V; Lakkisto, P; Mustonen, JT; Niemelä, OJ; Pörsti, IH; Tahvanainen, AM; Tikkanen, I; Vehmas, TI, 2008)
" A combination of short-term low-dose SPL and ARB is safe for patients with stage 1-3a CKD, but blood potassium must be regularly monitored."	3.11	Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study. ( Chang, L; Chen, H; He, L; Tian, R; Wang, Y; Ye, X; Yu, D; Zhang, H; Zhu, B, 2022)
" Twenty-seven male participants aged 23-45 years were randomized 3:1 to receive oral AZD9977 or placebo for 8 days (with twice-daily dosing on days 2-7), in dose cohorts of 50, 150, and 300 mg (AZD9977, n = 6 per cohort; placebo, n = 3 per cohort)."	2.94	Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. ( Albayaty, M; Backlund, A; Ericsson, H; Forte, P; Greasley, PJ; Hartleib-Geschwindner, J; Heijer, M; Kjaer, M; Kragh, ÅM; Unwin, R; Wernevik, L; Whittaker, A, 2020)
"Hypertension is prevalent in chronic kidney disease (CKD)."	2.87	Non-uniform relationship between salt status and aldosterone activity in patients with chronic kidney disease. ( Andrew, R; Freel, EM; Homer, NZM; Jardine, AG; Mark, PB; McQuarrie, EP; Rankin, AJ; Taylor, AHM, 2018)
"Metabolic acidosis affects about 15% of patients with chronic kidney disease."	2.82	Acid-Mediated Kidney Injury Across the Spectrum of Metabolic Acidosis. ( Pao, AC; Raphael, KL; Ravikumar, NPG, 2022)
"Aldosterone has emerged as an important mediator of disease progression and mortality in patients with chronic heart and kidney disease (CKD)."	2.75	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. ( Edwards, NC; Ferro, CJ; Hammer, F; Hughes, BA; Steeds, RP; Stewart, PM; Townend, JN, 2010)
" The efficacy of MMF as an immunosuppressant and long-term safety in cats of this dosage regimen is unknown."	2.61	( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
"Metabolic acidosis is defined as a pathologic process that, when unopposed, increases the concentration of hydrogen ions (H+) in the body and reduces the bicarbonate (HCO3-) concentration."	2.61	Hyperchloremic normal gap metabolic acidosis. ( Clegg, DJ; Palmer, BF, 2019)
"In contrast to distal type I or classic renal tubular acidosis (RTA) that is associated with hypokalemia, hyperkalemic forms of RTA also occur usually in the setting of mild-to-moderate CKD."	2.58	Hyperkalemic Forms of Renal Tubular Acidosis: Clinical and Pathophysiological Aspects. ( Arruda, J; Batlle, D, 2018)
"Aldosterone also promotes collagen synthesis, which leads to increased arterial stiffness and elevation of blood pressure."	2.53	Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. ( Duprez, DA; Epstein, M, 2016)
"19."	2.53	Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. ( Bomback, AS, 2016)
" The dose-response relationship for natriuresis with spironolactone has not been explored completely as to its combination therapy responses."	2.50	Aldosterone and volume management in hypertensive heart disease. ( Sica, DA, 2014)
"Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk."	2.50	Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014)
"Aldosterone is a downstream effector of angiotensin II in the renin-angiotensin-aldosterone system and binds to the mineralocorticoid receptor."	2.49	Aldosterone receptor antagonists: current perspectives and therapies. ( Ahmed, MI; Calhoun, DA; Clark, D; Guichard, JL, 2013)
"Addition of MR antagonists to standard treatment for hypertension and cardiac or renal disease decreases end-organ pathology and sympathetic nerve activation (SNA), and increases quality of life indices."	2.48	The ubiquitous mineralocorticoid receptor: clinical implications. ( Gomez-Sanchez, CE; Gomez-Sanchez, CM; Gomez-Sanchez, EP; Hawkins, UA, 2012)
"Aldosterone was a significant predictor of a CACS>100 AU in patients with CKD, but aldosterone was not a better predictor than age alone."	1.91	The Predictive Value of Serum Aldosterone Level for Coronary Artery Calcium Score in Patients with Chronic Kidney Disease: A Single-center Study. ( Bosdriesz, JR; Kuryata, O; Semenov, VV, 2023)
"Renin-independent aldosteronism (RIA) describes the spectrum of autonomous aldosterone secretion from mild to overt."	1.91	Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses. ( Chen, X; Cheng, Q; Gong, L; Hu, J; Li, Q; Luo, W; Luo, Y; Shu, X; Wang, Z; Yang, J; Yang, S; Zeng, Q, 2023)
"Hyperkalemia is a common complication of RAASi therapy and is associated with an increased risk of multiple adverse outcomes."	1.91	Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. ( Johnson, M; McMahon, G; Morrison, FJ; Su, M; Turchin, A, 2023)
"Renal fibrosis is the inevitable pathway of the progression of chronic kidney disease to end-stage renal disease, which manifests as progressive glomerulosclerosis and renal interstitial fibrosis."	1.72	Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone. ( Chang, Y; Gao, X; Han, Y; Hao, J; Liang, L; Qiang, P; Shimosawa, T; Xian, Y; Xiong, Y; Xu, Q; Yang, F, 2022)
"Hyperkalemia is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD)."	1.72	Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective. ( Fischer, B; Serra, A; Telser, H, 2022)
"Primary aldosteronism (PA) is the most common and potentially curable endocrine cause of secondary hypertension, and carries a worse prognosis than essential hypertension."	1.72	Screening for primary aldosteronism is underutilised in patients with chronic kidney disease. ( Chauhan, K; Fuller, PJ; Hutton, H; Kerr, PG; Libianto, R; Ryan, J; Schachna, E; Wilson, S; Yang, J, 2022)
"Residual hypertension was defined as persistent hypertension > 140/90 mmHg or requiring anti-hypertensive medications 1 year after surgery."	1.62	Comparison of cystatin C-based and creatinine-based glomerular filtration rate in the prediction of postoperative residual hypertension in aldosterone-producing adenoma patients after adrenalectomy. ( Chang, CC; Chen, CW; Chiu, YW; Hung, CS; Liao, SC; Lin, YH; Liu, KL; Tsai, CH; Tsai, IJ; Wu, VC, 2021)
"Aldosterone-treated mice exhibited an increased kidney injury and DNA damage in distal and proximal tubuli."	1.56	Aldosterone Induces DNA Damage and Activation of Nrf2 Mainly in Tubuli of Mouse Kidneys. ( Balhorn, R; Hartmann, C; Schupp, N, 2020)
"In patients with CKD, untreated chronic metabolic acidosis often leads to an accelerated reduction in GFR."	1.56	Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease. ( Bushinsky, DA; Buysse, JM; Wesson, DE, 2020)
"Aldosterone has an important role in the progression of renal fibrosis."	1.51	Aldosterone induces renal fibrosis by promoting HDAC1 expression, deacetylating H3K9 and inhibiting klotho transcription. ( Cheng, P; Gu, Y; Lai, L; Xue, J; Yan, M, 2019)
"Aldosterone levels were positively associated with CKD stage, and were inversely correlated with circulating α-klotho levels."	1.48	Circulating α-Klotho is Related to Plasma Aldosterone and Its Follow-Up Change Predicts CKD Progression. ( Cheng, P; Gu, Y; Hao, C; Lai, L; Qian, J; Shi, H; Yan, M; Zhong, J, 2018)
"Mean aldosterone levels were highest in the TT group and lowest in CC group (p = 0."	1.48	Modulation of aldosterone levels by aldosterone synthase promoter polymorphism and association with eGFR decline in patients with chronic kidney disease. ( Gu, Y; Hao, C; Lai, L; Qian, J; Shi, H; Yan, M; Zhong, J, 2018)
" Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients."	1.46	Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017)
"An experimental biomodel of chronic renal insufficiency induced by ischemia was developed using selective renal artery embolization (remnant kidney porcine model)."	1.46	The effect of renal denervation in an experimental model of chronic renal insufficiency, The REmnant kidney Denervation In Pigs study (REDIP study). ( Chochola, M; Fingrová, Z; Havránek, Š; Huang, KA; Kuchynková, S; Linhart, A; Lubanda, JC; Marek, J; Mlček, M; Neužil, P, 2017)
"Aldosterone (Aldo) is an independent risk factor for chronic kidney disease (CKD), and although Aldo directly induces renal tubular cell injury, the underlying mechanisms remain unclear."	1.43	Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. ( Ding, F; Ding, W; Guo, H; Wang, B; Xu, C; Zhang, M, 2016)
"Aldosterone was associated with congestive heart failure (adjusted hazard ratio, 1."	1.40	Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. ( Bansal, N; Deo, R; Feldman, HI; Keane, MG; Khan, AM; Leonard, MB; Shlipak, MG; Soliman, EZ; Steigerwalt, S; Townsend, RR; Yang, W; Zhang, X, 2014)
"Sudden cardiac death is common and accounts largely for the excess mortality of patients on maintenance dialysis."	1.39	Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. ( Allolio, B; Bidlingmaier, M; Blouin, K; Drechsler, C; Fassnacht, M; Hammer, F; Krane, V; März, W; Pilz, S; Ritz, E; Schönfeld, S; Tomaschitz, A; Wanner, C, 2013)

Research

Studies (120)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Albuminuria

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (1.67)	29.6817
2010's	76 (63.33)	24.3611
2020's	42 (35.00)	2.80

Authors	Studies
Hammer, F	3
Buehling, SS	1
Masyout, J	1
Malzahn, U	1
Hauser, T	1
Auer, T	1
Grebe, S	1
Feger, M	2
Tuffaha, R	1
Degenhart, G	1
Lang, F	4
Pasch, A	1
Alesutan, I	4
Wanner, C	2
Krane, V	2
Voelkl, J	4
Lin, M	2
Heizhati, M	2
Gan, L	2
Yao, X	1
Luo, Q	1
Zhang, D	1
Abulikemu, S	1
Wang, M	2
Wang, G	1
Jiang, W	2
Hu, J	2
Maimaiti, N	1
Wang, L	1
Wu, T	2
Sun, L	1
Yue, N	1
Ren, Y	1
Li, N	2
Wu, Y	1
Yang, H	1
Xu, S	1
Cheng, M	1
Gu, J	1
Zhang, W	2
Liu, S	1
Zhang, M	3
Grandt, LM	1
Schweighauser, A	1
Kovacevic, A	1
Francey, T	1
Chauhan, K	1
Schachna, E	1
Libianto, R	1
Ryan, J	1
Hutton, H	1
Fuller, PJ	1
Wilson, S	1
Kerr, PG	1
Yang, J	2
Zhang, H	2
Zhu, B	1
Chang, L	1
Ye, X	1
Tian, R	1
He, L	1
Yu, D	1
Chen, H	2
Wang, Y	5
Fischer, B	1
Serra, A	1
Telser, H	1
Hong, J	1
Xiamili, Z	1
Tong, L	1
Lin, Y	1
Chang, X	1
Hao, J	6
Wang, X	4
Liu, J	3
Ni, J	1
Hao, L	1
Epstein, M	4
Kovesdy, CP	1
Clase, CM	1
Sood, MM	1
Pecoits-Filho, R	1
Qiang, P	5
Yang, F	5
Han, Y	4
Chang, Y	5
Xian, Y	4
Xiong, Y	2
Gao, X	6
Liang, L	1
Shimosawa, T	5
Xu, Q	5
Ravikumar, NPG	1
Pao, AC	1
Raphael, KL	1
Ben, Y	1
Li, H	1
Chen, G	3
Ma, X	1
Verma, A	1
Vaidya, A	1
Subudhi, S	1
Waikar, SS	1
Ames, MK	1
Vaden, SL	1
Atkins, CE	1
Palerme, JS	1
Langston, CE	1
Grauer, GF	1
Shropshire, S	1
Bove, C	1
Webb, T	1
Close, SB	3
van Horn, JE	3
Wibbelink, CJM	3
Elias, MJ	3
DeLaney, EN	3
Williams, CD	3
Hawa, S	3
Walker, CJ	3
Lozada, FT	3
Su, J	3
Dick, DM	3
Dong, YH	3
Hu, JJ	3
Deng, F	3
Chen, XD	3
Li, C	5
Liu, KX	3
Zhao, BC	3
Kai, M	3
Ohishi, T	3
Hikasa, Y	3
Zheng, H	2
Ji, J	3
Zhao, T	2
Wang, E	2
Zhang, A	2
Johnson, M	1
Morrison, FJ	1
McMahon, G	1
Su, M	1
Turchin, A	1
Kanda, E	1
Rastogi, A	1
Murohara, T	1
Lesén, E	1
Agiro, A	2
Arnold, M	1
Yajima, T	1
Järbrink, K	1
Pollack, CV	1
Saritas, T	1
Floege, J	1
Ward, T	1
Lewis, RD	1
Brown, T	1
Baxter, G	1
de Arellano, AR	1
Sudani, HA	1
Shah, S	1
Lo, KB	1
Essa, H	1
Wattoo, A	1
Angelim, L	1
Brousas, S	1
Whybrow-Huppatz, I	1
Vellanki, S	1
Sankaranarayanan, R	1
Rangaswami, J	1
Fujii, W	1
Shibata, S	1
An, J	1
Zhou, H	1
Ni, L	2
Harrision, TN	1
Wei, R	1
Brahmbhatt, YG	1
Oluwatosin, Y	1
Schilling, CG	1
Sim, JJ	1
Chen, X	3
Luo, Y	1
Zeng, Q	1
Luo, W	1
Shu, X	1
Cheng, Q	1
Gong, L	1
Wang, Z	3
Li, Q	1
Yang, S	2
Giannese, D	1
D'Alessandro, C	1
Pellegrino, N	1
Panichi, V	1
Cupisti, A	1
Williams, JG	1
Hess, RS	1
Dattani, R	1
Ul-Haq, Z	1
Shah, M	1
Goldet, G	1
Darzi, LA	1
Ashrafian, H	1
Kamalati, T	1
Frankel, AH	1
Tam, FWK	1
Chinnadurai, R	1
Rengarajan, S	1
Budden, JJ	1
Quinn, CM	1
Kalra, PA	1
Semenov, VV	1
Bosdriesz, JR	1
Kuryata, O	1
Bobenko, AI	1
Heller, S	1
Schmitt, N	1
Cherdtrakulkiat, R	1
Lawung, R	1
Nabu, S	1
Tantimavanich, S	1
Sinthupoom, N	1
Prachayasittikul, S	1
Prachayasittikul, V	1
Zhang, B	1
Wu, C	1
Zhang, Z	2
Yan, K	1
Li, Y	4
Li, L	3
Zheng, C	1
Xiao, Y	1
He, D	1
Zhao, F	1
Su, JF	1
Lun, SM	1
Hou, YJ	1
Duan, LJ	1
Wang, NC	1
Shen, FF	1
Zhang, YW	1
Gao, ZW	1
Li, J	5
Du, XJ	1
Zhou, FY	1
Yin, Z	1
Zhu, J	2
Yan, D	1
Lou, H	1
Yu, H	1
Feng, C	1
Hu, X	1
Li, Z	2
Shen, Y	1
Hu, D	1
Wu, X	1
Duan, Y	1
Zhi, D	1
Zou, M	2
Zhao, Z	1
Zhang, X	3
Yang, X	2
Zhang, J	3
Wang, H	1
Popović, KJ	1
Popović, DJ	1
Miljković, D	1
Lalošević, D	1
Čapo, I	1
Popović, JK	1
Liu, M	1
Song, H	2
Xing, Z	1
Lu, G	1
Chen, D	1
Valentini, AM	1
Di Pinto, F	1
Coletta, S	1
Guerra, V	1
Armentano, R	1
Caruso, ML	1
Gong, J	1
Wang, N	1
Bian, L	1
Ye, M	1
Wen, N	1
Fu, M	1
Fan, W	1
Meng, Y	1
Dong, G	1
Lin, XH	1
Liu, HH	1
Gao, DM	1
Cui, JF	1
Ren, ZG	1
Chen, RX	1
Önal, B	1
Özen, D	1
Demir, B	1
Akkan, AG	1
Özyazgan, S	1
Payette, G	1
Geoffroy, V	1
Martineau, C	1
Villemur, R	1
Jameel, T	1
Baig, M	1
Gazzaz, ZJ	1
Tashkandi, JM	1
Al Alhareth, NS	1
Khan, SA	1
Butt, NS	1
Wang, J	2
Geng, Y	1
Zhang, Y	3
Basit, A	1
Miao, T	1
Liu, W	1
Yu, ZY	1
Wu, L	2
Qu, B	1
Sun, JX	1
Cai, AL	1
Xie, LM	1
Groeneveld, J	1
Ho, SL	1
Mackensen, A	1
Mohtadi, M	1
Laepple, T	1
Genovesi, S	1
Nava, E	1
Bartolucci, C	1
Severi, S	1
Vincenti, A	1
Contaldo, G	1
Bigatti, G	1
Ciurlino, D	1
Bertoli, SV	1
Slovak, JE	1
Hwang, JK	1
Rivera, SM	1
Villarino, NF	1
Li, S	1
Cao, G	1
Ling, M	1
Zhao, D	1
Sha, Y	1
Liang, C	2
Guo, Q	1
Zhou, C	1
Ma, Z	1
Xu, J	1
Wang, C	1
Zhao, W	1
Xia, X	1
Jiang, Y	1
Peng, J	1
Jia, Z	1
Li, F	1
Mo, J	1
Zhang, S	2
Li, X	1
Huang, T	1
Zhu, Q	1
Wang, S	1
Ge, RS	1
Fortunato, G	1
Lin, J	2
Agarwal, PK	1
Kohen, A	1
Singh, P	1
Cheatum, CM	1
Zhu, D	1
Hayman, A	1
Kebede, B	1
Stewart, I	1
Frew, R	1
Guo, X	1
Gong, Q	1
Borowiec, J	1
Han, S	1
Willis, M	1
Kreouzis, T	1
Yu, K	1
Chirvony, VS	1
Sekerbayev, KS	1
Pérez-Del-Rey, D	1
Martínez-Pastor, JP	1
Palazon, F	1
Boix, PP	1
Taurbayev, TI	1
Sessolo, M	1
Bolink, HJ	1
Lu, M	2
Lan, Y	1
Xiao, J	1
Song, M	1
Chen, C	1
Huang, Q	1
Cao, Y	1
Ho, CT	1
Qi, B	1
Wang, Q	1
Fang, L	1
Xie, CL	1
Chen, R	1
Xia, JM	1
Zhang, GY	1
Chen, CH	1
Yang, XW	1
Domenech-Ximenos, B	1
Garza, MS	1
Prat-González, S	1
Sepúlveda-Martínez, Á	1
Crispi, F	1
Perea, RJ	1
Garcia-Alvarez, A	1
Sitges, M	1
Kalumpha, M	1
Guyo, U	1
Zinyama, NP	1
Vakira, FM	1
Nyamunda, BC	1
Varga, M	1
Drácz, L	1
Kolbenheyer, E	1
Varga, F	1
Patai, ÁV	1
Solymosi, N	1
Patai, Á	1
Kiss, J	1
Gaál, V	1
Nyul, Z	1
Mosdósi, B	1
Valdez, M	1
Moosavi, L	1
Heidari, A	1
Novakovic-Agopian, T	1
Kornblith, E	1
Abrams, G	1
McQuaid, JR	1
Posecion, L	1
Burciaga, J	1
D'Esposito, M	1
Chen, AJW	1
Samy El Gendy, NM	1
Wesolowska, P	1
Georg, D	1
Lechner, W	1
Kazantsev, P	1
Bokulic, T	1
Tedgren, AC	1
Adolfsson, E	1
Campos, AM	1
Alves, VGL	1
Suming, L	1
Hao, W	1
Ekendahl, D	1
Koniarova, I	1
Bulski, W	1
Chelminski, K	1
Samper, JLA	1
Vinatha, SP	1
Rakshit, S	1
Siri, S	1
Tomsejm, M	1
Tenhunen, M	1
Povall, J	1
Kry, SF	1
Followill, DS	1
Thwaites, DI	1
Izewska, J	1
Kang, JH	1
Yoon, Y	1
Song, J	1
Van de Winckel, A	1
Gauthier, L	1
Chao, CT	1
Lee, YH	1
Li, CM	1
Han, DS	1
Huang, JW	1
Huang, KC	1
Güttinger, R	1
Triana, CA	1
Spingler, B	1
Baldridge, KK	1
Patzke, GR	1
Shen, X	1
Wang, B	2
Xie, S	1
Deng, W	1
Wu, D	1
Zhang, Q	1
Voskamp, BJ	1
Peelen, MJCS	1
Ravelli, ACJ	1
van der Lee, R	1
Mol, BWJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) or Other Cause of Chronic Renal Disease Compared to Healthy Volunteers[NCT04363554]		51 participants (Actual)	Interventional	2017-09-25	Completed
Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia：A Multicenter Randomized Controlled Study[NCT05688579]	Phase 4	8,000 participants (Anticipated)	Interventional	2023-04-16	Enrolling by invitation
HALT Progression of Polycystic Kidney Disease Study B[NCT01885559]	Phase 3	486 participants (Actual)	Interventional	2006-01-31	Completed
Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients[NCT01128101]	Phase 4	60 participants (Anticipated)	Interventional	2011-03-31	Recruiting
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?[NCT00291720]	Phase 2	120 participants (Actual)	Interventional	2005-04-30	Completed
Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493]	Phase 3	33 participants (Actual)	Interventional	2014-11-07	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Aldosterone

Intervention	annual percent change (Mean)
ACE-I + Placebo	7.5
ACE-I + ARB	7.3

Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years. (NCT01885559)
Timeframe: up at 8 years (annually assessed)

Back or Flank Pain

Intervention	annual percent change (Mean)
ACE-I + Placebo	-8.8
ACE-I + ARB	-10.2

Report of back or flank pain since the last visit (yes or no) (NCT01885559)
Timeframe: 48 months

Cardiovascular Hospitalizations

Intervention	percentage of participants at 48 months (Number)
ACE-I + Placebo	43
ACE-I + ARB	46

Cause-specific hospitalizations (cardiovascular) (NCT01885559)
Timeframe: up to 8 years

Hospitalizations

Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.

Intervention	events (Number)
ACE-I + Placebo	29
ACE-I + ARB	16

Intervention	events (Number)
ACE-I + Placebo	173
ACE-I + ARB	136

(NCT01885559)
Timeframe: Patients followed for 5-8 years with average of 6.5 years follow up

Quality of Life Mental Component Summary

Intervention	participants (Number)
ACE-I + Placebo	116
ACE-I + ARB	115

Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Quality of Life Physical Component Summary

Intervention	units on a scale per year (Mean)
ACE-I + Placebo	-0.031
ACE-I + ARB	-0.079

Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years. (NCT01885559)
Timeframe: up to 8 years (annually assessed)

Article	Year
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022, Volume: 80, Issue:5 Topics: Aldosterone; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hyperkalemia; Inflammation; Mineralocortic	2022
Acid-Mediated Kidney Injury Across the Spectrum of Metabolic Acidosis. Advances in chronic kidney disease, 2022, Volume: 29, Issue:4 Topics: Acidosis; Aldosterone; Ammonium Compounds; Angiotensin II; Citrates; Endothelin-1; Humans; Kidney; R	2022
Journal of family violence, 2022, Nov-21 Topics: Aldosterone; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eplerenone; Renal Insufficiency,	2022
Journal of family violence, 2022, Nov-21 Topics: Aldosterone; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eplerenone; Renal Insufficiency,	2022
Journal of family violence, 2022, Nov-21 Topics: Aldosterone; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eplerenone; Renal Insufficiency,	2022
Journal of family violence, 2022, Nov-21 Topics: Aldosterone; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eplerenone; Renal Insufficiency,	2022
[Retarding progression of chronic kidney disease]. Innere Medizin (Heidelberg, Germany), 2023, Volume: 64, Issue:3 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Humans; Mineralocorticoid Receptor Antagonist	2023
"Renalism" with Renin Angiotensin Aldosterone System Inhibitor Use in Patients Enrolled in Trials for Heart Failure with Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Systematic Review. Current vascular pharmacology, 2023, Volume: 21, Issue:2 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2023
Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges. International journal of molecular sciences, 2023, Apr-23, Volume: 24, Issue:9 Topics: Albuminuria; Aldosterone; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Receptors, Mineral	2023
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P	2019
Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how? Current opinion in nephrology and hypertension, 2020, Volume: 29, Issue:2 Topics: Aldosterone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Potassium; Renal Insuffi	2020
Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease. Journal of veterinary pharmacology and therapeutics, 2020, Volume: 43, Issue:3 Topics: Aldosterone; Animals; Cat Diseases; Cats; Gene Expression Regulation; Receptors, Mineralocorticoid;	2020
When should we start and stop ACEi/ARB in paediatric chronic kidney disease? Pediatric nephrology (Berlin, Germany), 2021, Volume: 36, Issue:7 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2021
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present. American journal of nephrology, 2021, Volume: 52, Issue:3 Topics: Aldosterone; Cardiovascular Diseases; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines	2021
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society Journal of hypertension, 2018, Volume: 36, Issue:3 Topics: Aldosterone; Animals; Arterial Pressure; Consensus; Endothelin-1; Endothelium, Vascular; Fibrosis; G	2018
Retarding progression of chronic kidney disease: use of modalities that counter acid retention. Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:2 Topics: Acid-Base Imbalance; Aldosterone; Angiotensin II; Animals; Buffers; Citrates; Dietary Proteins; Dise	2018
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:3 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics;	2018
Hyperkalemic Forms of Renal Tubular Acidosis: Clinical and Pathophysiological Aspects. Advances in chronic kidney disease, 2018, Volume: 25, Issue:4 Topics: Acidosis, Renal Tubular; Aldosterone; Animals; Epithelial Sodium Channels; Humans; Hydrogen-Ion Conc	2018
Hyperchloremic normal gap metabolic acidosis. Minerva endocrinologica, 2019, Volume: 44, Issue:4 Topics: Acid-Base Equilibrium; Acidosis; Acidosis, Renal Tubular; Aldosterone; Ammonia; Bicarbonates; Buffer	2019
[Antifibrotic renal role of mineralcorticoid receptor antagonists]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2019, Jul-24, Volume: 36, Issue:4 Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nep	2019
Vascular calcification--is aldosterone a culprit? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:5 Topics: Aldosterone; Animals; Humans; Hyperphosphatemia; Mice; Renal Insufficiency, Chronic; Vascular Calcif	2013
Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection. Contributions to nephrology, 2013, Volume: 179 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2013
Biomarkers for incident CKD: a new framework for interpreting the literature. Nature reviews. Nephrology, 2013, Volume: 9, Issue:8 Topics: Acute-Phase Proteins; Aldosterone; Biomarkers; Connective Tissue Growth Factor; Creatinine; Cystatin	2013
Aldosterone receptor antagonists: current perspectives and therapies. Vascular health and risk management, 2013, Volume: 9 Topics: Aldosterone; Animals; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Mineralocorticoid Rec	2013
Aldosterone and the kidney: a rapidly moving frontier (an update). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014, Volume: 29, Issue:11 Topics: Aldosterone; Animals; Humans; Kidney; Nephrons; Receptors, Mineralocorticoid; Renal Insufficiency, C	2014
Comparison of agents that affect aldosterone action. Seminars in nephrology, 2014, Volume: 34, Issue:3 Topics: Aldosterone; Animals; Epithelial Sodium Channel Blockers; Humans; Hydrocortisone; Hyperaldosteronism	2014
Aldosterone blockade in chronic kidney disease. Seminars in nephrology, 2014, Volume: 34, Issue:3 Topics: Aldosterone; Animals; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid;	2014
Aldosterone and volume management in hypertensive heart disease. Seminars in nephrology, 2014, Volume: 34, Issue:3 Topics: Aldosterone; Area Under Curve; Diuretics; Eplerenone; Heart Failure; Humans; Hypertension; Mineraloc	2014
Impact of aldosterone on osteoinductive signaling and vascular calcification. Nephron. Physiology, 2014, Volume: 128, Issue:1-2 Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hyperphosphatemia; Mice; Mineralocorticoid Re	2014
Pathogenesis of drug-resistant hypertension. Seminars in nephrology, 2014, Volume: 34, Issue:5 Topics: Age Factors; Aldosterone; Blood Pressure; Coronary Vasospasm; Drug Resistance; Humans; Hypertension;	2014
Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome? Advances in chronic kidney disease, 2014, Volume: 21, Issue:6 Topics: Aldosterone; Antihypertensive Agents; Blood Volume; Cardio-Renal Syndrome; Coronary Vasospasm; Diure	2014
Recent topics on podocytes and aldosterone. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2015, Volume: 25, Issue:2 Topics: Aldosterone; Animals; Disease Models, Animal; Humans; Hypertension; Metabolic Syndrome; Mice; Podocy	2015
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circulation research, 2015, Mar-13, Volume: 116, Issue:6 Topics: Aldosterone; Animals; Antihypertensive Agents; Dyslipidemias; Heart Conduction System; Hemodynamics;	2015
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. The lancet. Diabetes & endocrinology, 2015, Volume: 3, Issue:12 Topics: Aldosterone; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Mineralocorticoid R	2015
Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety. Blood purification, 2016, Volume: 41, Issue:1-3 Topics: Aldosterone; Blood Pressure; Disease Progression; Eplerenone; Heart Failure; Humans; Kidney Failure,	2016
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016. The American journal of medicine, 2016, Volume: 129, Issue:7 Topics: Age Factors; Aldosterone; Blood Pressure Monitoring, Ambulatory; Comorbidity; Diabetes Mellitus; Hum	2016
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:4 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressu	2016
Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients. Therapeutic advances in cardiovascular disease, 2016, Volume: 10, Issue:5 Topics: Aldosterone; Body Mass Index; C-Reactive Protein; Humans; Hypertrophy, Left Ventricular; Renal Dialy	2016
[Mechanisms responsible for the renoprotective effects of renin-angiotensin inhibitors]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2012, Volume: 132, Issue:4 Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Humans; Hypertension;	2012
Angiotensin II-mediated left ventricular abnormalities in chronic kidney disease. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2012, Volume: 60, Issue:5 Topics: Aldosterone; Angiotensin II; Animals; Heart Ventricles; Humans; Renal Insufficiency, Chronic; Ventri	2012
The ubiquitous mineralocorticoid receptor: clinical implications. Current hypertension reports, 2012, Volume: 14, Issue:6 Topics: Aldosterone; Cardiovascular Diseases; Glucocorticoids; Humans; Hypertension; Mineralocorticoid Recep	2012
The incidence and implications of aldosterone breakthrough. Nature clinical practice. Nephrology, 2007, Volume: 3, Issue:9 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Huma	2007

Article	Year
Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochemical and biophysical research communications, 2021, 12-10, Volume: 582 Topics: Aldosterone; Alkaline Phosphatase; Animals; Aorta; Biomarkers; Cholecalciferol; Core Binding Factor	2021
Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study. BMC nephrology, 2022, 03-05, Volume: 23, Issue:1 Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diet, Sodiu	2022
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. Clinical and translational science, 2020, Volume: 13, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aldosterone; Area Under Curve; Benzoates; Dose-Response Rel	2020
Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease. Annals of medicine, 2017, Volume: 49, Issue:6 Topics: Adult; Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Female	2017
Non-uniform relationship between salt status and aldosterone activity in patients with chronic kidney disease. Clinical science (London, England : 1979), 2018, 01-31, Volume: 132, Issue:2 Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Cross-Over Studies; Diet, Sodium-Restricte	2018
Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level. Hypertension research : official journal of the Japanese Society of Hypertension, 2018, Volume: 41, Issue:6 Topics: Aged; Aldosterone; Amides; Antihypertensive Agents; Blood Pressure; Female; Fumarates; Humans; Hyper	2018
Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. Journal of clinical hypertension (Greenwich, Conn.), 2014, Volume: 16, Issue:9 Topics: Adult; Aged; Aldosterone; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diuretics; Dose-Res	2014
Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney international, 2015, Volume: 87, Issue:4 Topics: Adipose Tissue; Aged; Aldosterone; Amidohydrolases; Animals; Arginine; Cell Nucleus; Cytochrome P-45	2015
Impact of baroreflex activation therapy on renal function--a pilot study. American journal of nephrology, 2014, Volume: 40, Issue:4 Topics: Aged; Aldosterone; Baroreflex; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hypertens	2014
Angiotensin blockade in late autosomal dominant polycystic kidney disease. The New England journal of medicine, 2014, Dec-11, Volume: 371, Issue:24 Topics: Adolescent; Adult; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co	2014
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney international, 2016, Volume: 90, Issue:3 Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy	2016
The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clinical endocrinology, 2010, Volume: 73, Issue:5 Topics: Adrenal Cortex Hormones; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Female; Humans; H	2010
Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. International urology and nephrology, 2012, Volume: 44, Issue:3 Topics: Adult; Aldosterone; Amides; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihyper	2012
Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart and vessels, 2013, Volume: 28, Issue:4 Topics: Aged; Albuminuria; Aldosterone; Amides; Antihypertensive Agents; Biomarkers; Blood Pressure; Diabeti	2013
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart and vessels, 2013, Volume: 28, Issue:4 Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv	2013

Article	Year
Higher aldosterone is associated with increased renal impairment risk in patients with hypertension and abnormal glucose metabolism: a longitudinal study. Journal of hypertension, 2022, 03-01, Volume: 40, Issue:3 Topics: Aldosterone; Glomerular Filtration Rate; Glucose; Humans; Hypertension; Longitudinal Studies; Renal	2022
AIM2 inflammasome contributes to aldosterone-induced renal injury via endoplasmic reticulum stress. Clinical science (London, England : 1979), 2022, 01-14, Volume: 136, Issue:1 Topics: Acute Kidney Injury; Aldosterone; Animals; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Fibro	2022
The circulating renin-angiotensin-aldosterone system is down-regulated in dogs with glomerular diseases compared to other chronic kidney diseases with low-grade proteinuria. PloS one, 2022, Volume: 17, Issue:1 Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Azotemia; Blood Urea Nitrogen; Dog Diseases; Dogs;	2022
Screening for primary aldosteronism is underutilised in patients with chronic kidney disease. Journal of nephrology, 2022, Volume: 35, Issue:6 Topics: Adult; Aldosterone; Humans; Hyperaldosteronism; Hypertension; Potassium; Renal Insufficiency, Chroni	2022
Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective. Advances in therapy, 2022, Volume: 39, Issue:6 Topics: Aldosterone; Antihypertensive Agents; Cost-Benefit Analysis; Delivery of Health Care; Humans; Hyperk	2022
Higher plasma renin activity is associated with increased kidney damage risk in patients with hypertension and glucose metabolic disorders. Journal of clinical hypertension (Greenwich, Conn.), 2022, Volume: 24, Issue:6 Topics: Aldosterone; Glucose Metabolism Disorders; Humans; Hypertension; Kidney; Proteinuria; Renal Insuffic	2022
The Role of AIF-1 in the Aldosterone-Induced Vascular Calcification Related to Chronic Kidney Disease: Evidence From Mice Model and Cell Co-Culture Model. Frontiers in endocrinology, 2022, Volume: 13 Topics: Aldosterone; Animals; Coculture Techniques; Disease Models, Animal; Endothelial Cells; Mice; Mice, K	2022
Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone. Frontiers in immunology, 2022, Volume: 13 Topics: Aldosterone; Animals; Eplerenone; Fibrosis; Macrophages; Mice; Myofibroblasts; Pyrroles; Rats; Recep	2022
Eplerenone Prevents Cardiac Fibrosis by Inhibiting Angiogenesis in Unilateral Urinary Obstruction Rats. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2022, Volume: 2022 Topics: Actins; Aldosterone; Animals; Collagen; Eosine Yellowish-(YS); Eplerenone; Fibrosis; Glucocorticoids	2022
Aldosterone in chronic kidney disease and renal outcomes. European heart journal, 2022, 10-11, Volume: 43, Issue:38 Topics: Aldosterone; Diabetes Mellitus; Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Min	2022
Prevalence of aldosterone breakthrough in dogs receiving renin-angiotensin system inhibitors for proteinuric chronic kidney disease. Journal of veterinary internal medicine, 2022, Volume: 36, Issue:6 Topics: Aldosterone; Animals; Antihypertensive Agents; Creatinine; Dog Diseases; Dogs; Prevalence; Prospecti	2022
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway. International immunopharmacology, 2022, Volume: 113, Issue:Pt A Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof	2022
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway. International immunopharmacology, 2022, Volume: 113, Issue:Pt A Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof	2022
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway. International immunopharmacology, 2022, Volume: 113, Issue:Pt A Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof	2022
Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR/CTGF pathway. International immunopharmacology, 2022, Volume: 113, Issue:Pt A Topics: Aldosterone; Animals; Cardio-Renal Syndrome; Eplerenone; Fibrosis; Heart Diseases; Macrophages; Myof	2022
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway. International journal of molecular medicine, 2023, Volume: 51, Issue:2 Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis;	2023
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway. International journal of molecular medicine, 2023, Volume: 51, Issue:2 Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis;	2023
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway. International journal of molecular medicine, 2023, Volume: 51, Issue:2 Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis;	2023
Exosome‑encapsulated miR‑26a attenuates aldosterone‑induced tubulointerstitial fibrosis by inhibiting the CTGF/SMAD3 signaling pathway. International journal of molecular medicine, 2023, Volume: 51, Issue:2 Topics: 3' Untranslated Regions; Aldosterone; Animals; Connective Tissue Growth Factor; Exosomes; Fibrosis;	2023
Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor. American heart journal, 2023, Volume: 258 Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Coronary Arte	2023
Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC nephrology, 2023, 01-19, Volume: 24, Issue:1 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enzyme Inhibitors; H	2023
A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. BMC nephrology, 2023, 03-09, Volume: 24, Issue:1 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Effectiveness A	2023
Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. American journal of nephrology, 2023, Volume: 54, Issue:7-8 Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiov	2023
Renin-independent aldosteronism and chronic kidney disease in diabetes: Observational and Mendelian randomization analyses. Metabolism: clinical and experimental, 2023, Volume: 145 Topics: Aldosterone; Diabetes Mellitus; Genome-Wide Association Study; Humans; Hyperaldosteronism; Mendelian	2023
RAASi Therapy Attenuates the Association between 24-h Urinary Potassium Excretion and Dietary Potassium Intake in CKD Patients. Nutrients, 2023, May-24, Volume: 15, Issue:11 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Humans; Potassium; P	2023
Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension. Journal of feline medicine and surgery, 2023, Volume: 25, Issue:7 Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Diabetes Mellitus; Hy	2023
Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study. PloS one, 2023, Volume: 18, Issue:8 Topics: Albuminuria; Aldosterone; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypertension; London; Mi	2023
Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN. American journal of nephrology, 2023, Volume: 54, Issue:9-10 Topics: Adult; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mell	2023
The Predictive Value of Serum Aldosterone Level for Coronary Artery Calcium Score in Patients with Chronic Kidney Disease: A Single-center Study. Prague medical report, 2023, Volume: 124, Issue:3 Topics: Aldosterone; Area Under Curve; Calcium; Coronary Vessels; Humans; Renal Insufficiency, Chronic	2023
Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2021, 04-26, Volume: 36, Issue:5 Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Melli	2021
Mechanisms of Metabolic Acidosis-Induced Kidney Injury in Chronic Kidney Disease. Journal of the American Society of Nephrology : JASN, 2020, Volume: 31, Issue:3 Topics: Acid-Base Equilibrium; Acidosis; Adaptation, Physiological; Aldosterone; Angiotensin II; Biomarkers;	2020
Aldosterone Induces DNA Damage and Activation of Nrf2 Mainly in Tubuli of Mouse Kidneys. International journal of molecular sciences, 2020, Jun-30, Volume: 21, Issue:13 Topics: Aldosterone; Animals; Blood Pressure; DNA Damage; Kidney; Male; Mice, Inbred C57BL; NF-E2-Related Fa	2020
Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study. BMC nephrology, 2020, 08-31, Volume: 21, Issue:1 Topics: Adult; Aged; Aldosterone; Aquaporin 2; Case-Control Studies; Epithelial Sodium Channels; Female; Hum	2020
Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. European heart journal, 2021, 01-01, Volume: 42, Issue:1 Topics: Aldosterone; Diabetes Mellitus, Type 2; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridin	2021
Comparison of cystatin C-based and creatinine-based glomerular filtration rate in the prediction of postoperative residual hypertension in aldosterone-producing adenoma patients after adrenalectomy. Clinica chimica acta; international journal of clinical chemistry, 2021, Volume: 520 Topics: Adenoma; Adrenalectomy; Aldosterone; Biomarkers; Creatinine; Cystatin C; Glomerular Filtration Rate;	2021
Modern peptide biomarkers and echocardiography in cardiac healthy haemodialysis patients. BMC nephrology, 2017, May-30, Volume: 18, Issue:1 Topics: Adult; Aldosterone; Atrial Natriuretic Factor; Biomarkers; Echocardiography; Female; Glycopeptides;	2017
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. International urology and nephrology, 2017, Volume: 49, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch	2017
A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy. Scientific reports, 2017, 08-11, Volume: 7, Issue:1 Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Losartan; Mineralocorticoid Receptor	2017
PECULIARITIES OF REMODELING OF HEART AND NEUROHUMORAL STATUS IN PATIENTS WITH CHRONIC HEART FAILURE AND CONCOMITANT RENAL DISEASE DEPENDING ON THE VALUE OF THE EJECTION FRACTION OF THE LEFT VENTRICLE. Georgian medical news, 2017, Issue:270 Topics: Aldosterone; Chronic Disease; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocar	2017
The effect of renal denervation in an experimental model of chronic renal insufficiency, The REmnant kidney Denervation In Pigs study (REDIP study). Journal of translational medicine, 2017, 10-25, Volume: 15, Issue:1 Topics: Aldosterone; Animals; Creatinine; Denervation; Disease Models, Animal; Kidney; Renal Artery; Renal I	2017
Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PloS one, 2018, Volume: 13, Issue:2 Topics: Administration, Oral; Aldosterone; Animals; Benzoates; Cell Line, Tumor; Dose-Response Relationship,	2018
Olmesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease. Clinical and experimental hypertension (New York, N.Y. : 1993), 2019, Volume: 41, Issue:3 Topics: Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Combined Mo	2019
Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function. International urology and nephrology, 2018, Volume: 50, Issue:10 Topics: Adrenalectomy; Adult; Aldosterone; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; M	2018
Circulating α-Klotho is Related to Plasma Aldosterone and Its Follow-Up Change Predicts CKD Progression. Kidney & blood pressure research, 2018, Volume: 43, Issue:3 Topics: Aldosterone; Disease Progression; Follow-Up Studies; Glomerular Filtration Rate; Glucuronidase; Huma	2018
Ecdysone Elicits Chronic Renal Impairment via Mineralocorticoid-Like Pathogenic Activities. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 49, Issue:4 Topics: Aldosterone; Animals; Apoptosis; Blood Urea Nitrogen; Cell Dedifferentiation; Cell Line; Collagen; E	2018
Relation of multi-marker panel to incident chronic kidney disease and rapid kidney function decline in African Americans: the Jackson Heart Study. BMC nephrology, 2018, 09-20, Volume: 19, Issue:1 Topics: Adiponectin; Aldosterone; Biomarkers; Black or African American; C-Reactive Protein; Disease Progres	2018
The eNOS-NO pathway attenuates kidney dysfunction via suppression of inflammasome activation in aldosterone-induced renal injury model mice. PloS one, 2018, Volume: 13, Issue:10 Topics: Aldosterone; Animals; Antihypertensive Agents; Disease Models, Animal; Endothelium; Fibrosis; Humans	2018
Aldosterone induces albuminuria via matrix metalloproteinase-dependent damage of the endothelial glycocalyx. Kidney international, 2019, Volume: 95, Issue:1 Topics: Albuminuria; Aldosterone; Animals; Cell Line; Disease Models, Animal; Endothelial Cells; Glycocalyx;	2019
Aldosterone induces renal fibrosis by promoting HDAC1 expression, deacetylating H3K9 and inhibiting klotho transcription. Molecular medicine reports, 2019, Volume: 19, Issue:3 Topics: Acetylation; Adult; Aged; Aged, 80 and over; Aldosterone; Animals; Down-Regulation; Female; Fibronec	2019
Modulation of aldosterone levels by aldosterone synthase promoter polymorphism and association with eGFR decline in patients with chronic kidney disease. Discovery medicine, 2018, Volume: 26, Issue:145 Topics: Adult; Aged; Aldosterone; Cardiovascular Diseases; Cerebrovascular Disorders; Cytochrome P-450 CYP11	2018
Urinary sodium excretion is the main determinant of mineralocorticoid excretion rates in patients with chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:6 Topics: Aldosterone; Cohort Studies; Corticosterone; Cross-Sectional Studies; Essential Hypertension; Female	2013
Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy. PloS one, 2013, Volume: 8, Issue:2 Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Drug Therapy, Combi	2013
Urinary angiotensinogen as a potential biomarker of intrarenal renin-angiotensin system activity in Chinese chronic kidney disease patients. Irish journal of medical science, 2015, Volume: 184, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Angiotensinogen; Asian Peop	2015
Editorial: New horizon in the treatment of hypertension--role for Ca channel blockers--why do Ca channel blockers be focused on? Current hypertension reviews, 2013, Volume: 9, Issue:3 Topics: Aldosterone; Calcium Channel Blockers; Edema; Heart; Humans; Hypertension; Renal Insufficiency, Chro	2013
Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 64, Issue:1 Topics: Aged; Aldosterone; Black People; Cardiovascular Diseases; Female; Follow-Up Studies; Glomerular Filt	2014
Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease. Journal of the renin-angiotensin-aldosterone system : JRAAS, 2014, Volume: 15, Issue:3 Topics: Aged; Aldosterone; Case-Control Studies; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meie	2014
Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. American journal of physiology. Heart and circulatory physiology, 2014, Nov-15, Volume: 307, Issue:10 Topics: Adult; Aged; Aldosterone; Biomarkers; Cross-Sectional Studies; Female; Fibroblast Growth Factor-23;	2014
Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease. Hypertension research : official journal of the Japanese Society of Hypertension, 2015, Volume: 38, Issue:4 Topics: Adult; Aged; Aldosterone; Blood Pressure; Creatinine; Female; Humans; Hypertension; Hypertrophy, Lef	2015
Aldosterone and abnormal left ventricular geometry in chronic kidney disease. Hypertension research : official journal of the Japanese Society of Hypertension, 2015, Volume: 38, Issue:5 Topics: Aldosterone; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Renal Insufficiency,	2015
Systemic Aldosterone, But Not Angiotensin II, Plays a Pivotal Role in the Pathogenesis of Renal Injury in Chronic Nitric Oxide-Deficient Male Rats. Endocrinology, 2015, Volume: 156, Issue:7 Topics: Adrenalectomy; Aldosterone; Angiotensin II; Animals; Blood Pressure; Chemokine CCL2; Disease Models,	2015
Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells. BioMed research international, 2015, Volume: 2015 Topics: ADAM Proteins; ADAM17 Protein; Aldosterone; Cell Line; Cell Proliferation; Epithelial Cells; ErbB Re	2015
Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Area Under Curve; Biomarkers; Child; China;	2015
'To block or not to block'; whether to continue renin-angiotensin-aldosterone system blockade in advanced chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:2 Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Humans; Renal Insufficiency, Chronic; Renin;	2016
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model. Journal of pharmacological sciences, 2016, Volume: 130, Issue:2 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazol	2016
Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. Oncotarget, 2016, Apr-05, Volume: 7, Issue:14 Topics: Aldosterone; Animals; Cell Line; Humans; Inflammasomes; Kidney Tubules; Mice; Mice, Inbred C57BL; Mi	2016
Effects of Treating Primary Aldosteronism on Renal Function. Journal of clinical hypertension (Greenwich, Conn.), 2017, Volume: 19, Issue:3 Topics: Adrenalectomy; Adult; Aldosterone; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; M	2017
Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. Journal of hypertension, 2008, Volume: 26, Issue:8 Topics: Aldosterone; Animal Feed; Animals; Autoradiography; Blood Pressure; Disease Models, Animal; Hyperten	2008
[Aldosterone exacerbates chronic renal insufficiency]. Ugeskrift for laeger, 2011, Jan-24, Volume: 173, Issue:4 Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim	2011
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases]. Eksperimental'naia i klinicheskaia farmakologiia, 2011, Volume: 74, Issue:4 Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme In	2011
Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease. Clinical science (London, England : 1979), 2012, Volume: 123, Issue:5 Topics: Aged; Aldosterone; Biomarkers; Cross-Sectional Studies; Desoxycorticosterone; Female; Gas Chromatogr	2012
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. European heart journal, 2013, Volume: 34, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Anticholesteremic Agents; Atorvastatin; Dea	2013
Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. The Journal of clinical investigation, 2013, Volume: 123, Issue:2 Topics: Aldosterone; Animals; Cell Differentiation; Cells, Cultured; Fibroblast Growth Factor-23; Fibroblast	2013

aldosterone and Chronic Kidney Diseases